Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Rhea-AI Summary

Emergent BioSolutions (NYSE:EBS) has secured a $56 million contract modification from the U.S. government to supply ACAM2000®, a smallpox and mpox vaccine. The modification, under an existing 10-year contract with ASPR, will begin deliveries in September 2025.

Total projected sales for ACAM2000® vaccine and ancillary products are expected to exceed $120 million in 2025. The single-dose vaccine, which received FDA approval for smallpox in 2007 and mpox in August 2024, is currently stockpiled in the U.S. and internationally, with additional licenses in Canada, Australia, and Singapore.

Positive

• New $56 million contract modification from U.S. government
• Total projected ACAM2000® sales exceeding $120 million in 2025
• Recent FDA approval expansion to include mpox indication (August 2024)
• International market presence with licenses in multiple countries

Negative

• None.

Insights

Government Contracts Analyst

Emergent secures $56M contract modification for ACAM2000 vaccine, boosting 2025 vaccine sales to $120M+.

Emergent BioSolutions has secured a $56 million contract modification from the U.S. government for its ACAM2000 vaccine, with deliveries beginning this month. This development significantly increases the company's projected 2025 revenue from ACAM2000 vaccine and related products to over $120 million across multiple customers.

This contract modification occurs under Emergent's existing 10-year agreement with the Administration for Strategic Preparedness and Response (ASPR), demonstrating the continued strength of Emergent's government contracting business. The timing is particularly notable following the recent August 2024 FDA approval expanding ACAM2000's indication to include mpox immunization for high-risk individuals, in addition to its original 2007 approval for smallpox prevention.

The contract reinforces Emergent's position in the medical countermeasures market, leveraging their North American manufacturing capabilities and supply chain infrastructure. This represents a material revenue contribution to Emergent's product portfolio, particularly important as governments worldwide maintain vigilance against potential infectious disease threats. The expansion to multiple international markets (Canada, Australia, and Singapore) further diversifies the customer base beyond U.S. government contracts.

This development should be viewed as a validation of Emergent's strategic focus on government partnerships for public health preparedness, with the expanded mpox indication potentially opening additional revenue opportunities as global health authorities respond to infectious disease threats.

GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000^®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000^® vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000^® is licensed for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection.

“Our new contract modification for ACAM2000^® vaccine reflects the continued collaboration between Emergent and the U.S. government to prioritize preparedness support,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “With our North American manufacturing and supply chain capabilities at the ready, and Emergent’s commitment to being a trusted partner of the U.S. government and offering most favored pricing as part of that commitment, we are helping to strengthen public health efforts through our medical countermeasures portfolio.”

ACAM2000^® is a single-dose vaccine administered percutaneously via a bifurcated needle that is dipped into the vaccine solution that is used to prick the skin several times in the upper arm with a droplet of the vaccine. The vaccine was first approved by the U.S. Food and Drug Administration (FDA) in 2007 for active immunization for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection, and was FDA approved in August 2024 for immunization against mpox in individuals determined to be at high-risk for mpox. ACAM2000^® is also licensed for smallpox in Canada, Australia and Singapore and is currently stockpiled both in the U.S. and internationally.

This contract modification is under Emergent’s existing 10-year contract (75A50119C00071) with the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services.

About ACAM2000^®, (Smallpox and Mpox (Vaccinia) Vaccine, Live)

Indication

ACAM2000^® is indicated for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox and mpox infection.

Select Important Safety Information

Boxed Warning: Serious Complications
Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000 primary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum resulting in permanent sequelae or death, accidental eye infection (ocular vaccinia) which can cause ocular complications that may lead to blindness, and fetal death, have occurred following either primary vaccination or revaccination with ACAM2000^® or other live vaccinia virus vaccines that were used historically. These risks are increased in certain individuals and may result in severe disability, permanent neurological sequelae and/or death.

Contraindications: Do not administer ACAM2000^® to individuals with severe immunodeficiency. These individuals may include persons who are undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation.

Warnings & Precautions: Myocarditis and/or pericarditis, ischemic heart disease and non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum, fetal vaccinia, fetal death, and accidental eye infection (ocular vaccinia) that may lead to blindness.

Adverse Reactions: Inoculation site signs and symptoms, lymphadenitis, and constitutional symptoms, such as malaise, fatigue, fever, myalgia, and headache.

To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-877-246-8472 (U.S.), 1-800-768-2304 (Canada), or medicalinformation@ebsi.com; or VAERS at 1-800-822-7967 and https://vaers.hhs.gov.

Please see the full Prescribing Information for ACAM2000^® for complete Boxed Warning and safety information.

About Emergent BioSolutions 
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Safe Harbor Statement
This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the expected timing for delivery of the ACAM2000^® vaccine and projected sales of ACAM2000^®, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this communication and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause our actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

What is the value of Emergent BioSolutions' (EBS) new contract modification for ACAM2000?

The contract modification is valued at $56 million for supplying ACAM2000® vaccine to the U.S. government.

What are the projected sales for EBS's ACAM2000 vaccine in 2025?

Total projected sales for ACAM2000® vaccine and ancillary products are expected to exceed $120 million in 2025 from diverse customers.

When did ACAM2000 receive FDA approval for mpox treatment?

ACAM2000® received FDA approval for mpox immunization in August 2024 for individuals at high risk of mpox infection.

How is the ACAM2000 vaccine administered?

ACAM2000® is a single-dose vaccine administered percutaneously via a bifurcated needle that pricks the skin several times in the upper arm.

In which countries is EBS's ACAM2000 vaccine licensed?

ACAM2000® is licensed in the United States, Canada, Australia, and Singapore, and is stockpiled both in the U.S. and internationally.